ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 54 filers reported holding ADC THERAPEUTICS SA in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $50,019 | -58.3% | 55,762 | 0.0% | 0.00% | -66.7% |
| Q2 2023 | $119,888 | +10.3% | 55,762 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $108,736 | +22227.7% | 55,762 | -56.0% | 0.00% | -75.0% |
| Q4 2022 | $487 | -99.9% | 126,868 | -24.0% | 0.01% | -27.3% |
| Q3 2022 | $804,000 | -39.7% | 166,868 | -0.5% | 0.01% | -21.4% |
| Q2 2022 | $1,333,000 | -45.9% | 167,698 | 0.0% | 0.01% | -46.2% |
| Q1 2022 | $2,463,000 | -4.5% | 167,698 | +31.3% | 0.03% | 0.0% |
| Q4 2021 | $2,579,000 | -24.1% | 127,698 | +2.0% | 0.03% | -25.7% |
| Q3 2021 | $3,400,000 | -0.4% | 125,198 | -10.7% | 0.04% | +9.4% |
| Q2 2021 | $3,414,000 | +26.9% | 140,198 | +27.2% | 0.03% | +23.1% |
| Q1 2021 | $2,690,000 | -23.7% | 110,198 | 0.0% | 0.03% | -48.0% |
| Q4 2020 | $3,527,000 | -92.9% | 110,198 | -93.2% | 0.05% | -94.3% |
| Q3 2020 | $49,373,000 | -23.4% | 1,623,210 | +3.8% | 0.87% | -54.1% |
| Q2 2020 | $64,414,000 | – | 1,563,438 | – | 1.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,680,149 | $24,681,000 | 9.63% |
| Grosvenor Holdings, L.L.C. | 1,517,212 | $22,288,000 | 4.35% |
| Redmile Group, LLC | 7,432,429 | $109,182,000 | 3.41% |
| MPM BioImpact LLC | 334,384 | $4,912,000 | 1.32% |
| Indie Asset Partners, LLC | 96,572 | $1,419,000 | 1.07% |
| Eventide Asset Management | 1,975,000 | $29,013,000 | 0.46% |
| HHLR ADVISORS, LTD. | 500,000 | $7,345,000 | 0.15% |
| Virtus ETF Advisers LLC | 19,193 | $282,000 | 0.13% |
| Walleye Capital LLC | 248,354 | $3,648,000 | 0.10% |
| Matrix Capital Management Company, LP | 400,000 | $5,876,000 | 0.07% |